High impact
Bloomberg reports AstraZeneca shares dropped over 10% after a heart drug trial failure in a rare disease patient group.
bloomberg-markets07/09, 09:06 PM
Related assets
Coming up for AZN
Explore next
Latest AZN news
Jin1008/17, 07:48 PM
Jin1008/17, 01:48 PM
Jin1008/05, 07:04 PM
Astrazeneca and Bristol Myers Squibb have no ongoing discussions regarding a potential transaction.